-
GeoVax Reports Third Quarter 2025 Financial Results and Provides Business Update
Quarter Highlighted by GEO-MVA Acceleration Amid Global Mpox Emergency, Gedeptin® Expansion into New Solid Tumor Programs, and Strong GEO-CM04S1 Clinical Data in Immunocompromised…
-
GeoVax Recognizes World Immunization Day: Advancing Innovation and Trust in Vaccination
Positioning GeoVax as a Diversified, Made-in-America Vaccine Leader with Global Market Relevance Atlanta, GA – November 10, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX),…
-
GeoVax to Report Third Quarter 2025 Financial Results and Provide Corporate Update on November 13, 2025
Atlanta, GA – November 4, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases…
-
GeoVax Announces Relocation of Corporate Headquarters and Laboratory Operations to Support Accelerated Growth and Pipeline Advancement
Relocations Strengthen Ties to Georgia’s Bio-Ecosystem and Position GeoVax for Late-Stage Development and Market Readiness Atlanta, GA – November 3, 2025 – GeoVax Labs,…
-
BIO CEO Warns U.S. Could Lose Biotech Leadership Within Two Years; GeoVax Calls on Congress and Administration to Act Now
Following John Crowley’s Testimony, GeoVax Highlights Urgent Need for Vaccine Platform Diversity, Onshoring Manufacturing, and Protecting Immunocompromised Populations Atlanta, GA — October 30,…
-
GeoVax Welcomes New IDSA Guidance Highlighting Need for Tailored COVID-19 Vaccines for Immunocompromised Patients
GEO-CM04S1 Designed to Deliver Broader, More Durable Protection for the 40 Million Americans Left Vulnerable by Limited Effectiveness of Current Vaccines Atlanta, GA…
-
GeoVax Highlights Urgent Need for Multisource Mpox Vaccine Supply Following California Clade 1 Cases
EMA Endorses Expedited Development Pathway for GEO-MVA; Company Advances U.S.-Based Continuous Cell Line Manufacturing to Address Fragile Supply Chains and Align with Federal…
-
GeoVax Highlights Positive Interim Results for Multi-Antigen COVID-19 Vaccine in Immunocompromised Patients at World Vaccine Congress Europe 2025
Presentations Underscore Favorable Safety Profile and Robust T-Cell Responses of GEO-CM04S1 in Vulnerable Populations ATLANTA, GA – October 16, 2025 – GeoVax Labs, Inc.…
-
GeoVax Leadership to Participate in Key European Meetings to Advance Partnering Discussions
Executives to Participate at World Vaccine Congress Europe (Amsterdam, Oct 13–16) and BIO-Europe Fall (Vienna, Nov 3–5), and Meet With NGOs, Industry Partners…
-
GeoVax to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2025
Presentations to Highlight Interim Safety Data and Special-Populations Insights for GEO-CM04S1 in Immunocompromised Patients ATLANTA, GA – October 9, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX),…
-
GeoVax to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
David Dodd, Chairman & CEO, Available for Investor Meetings ATLANTA, GA, October 7, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology…
-
GeoVax Labs Announces $2.5 Million Registered Direct Offering
ATLANTA, GA, September 30, 2025 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases,…